Metropolitan Life Insurance Co. NY held its position in Luminex Co. (NASDAQ:LMNX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,233 shares of the medical instruments supplier’s stock at the end of the first quarter. Metropolitan Life Insurance Co. NY’s holdings in Luminex were worth $519,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. raised its position in Luminex by 52,547.0% in the first quarter. BlackRock Inc. now owns 5,063,064 shares of the medical instruments supplier’s stock worth $93,008,000 after buying an additional 5,053,447 shares during the period. RGM Capital LLC raised its position in Luminex by 42.5% in the first quarter. RGM Capital LLC now owns 2,715,517 shares of the medical instruments supplier’s stock worth $49,884,000 after buying an additional 810,372 shares during the period. Norges Bank acquired a new position in Luminex during the fourth quarter worth $10,841,000. Elk Creek Partners LLC raised its position in Luminex by 152.0% in the first quarter. Elk Creek Partners LLC now owns 698,416 shares of the medical instruments supplier’s stock worth $12,830,000 after buying an additional 421,263 shares during the period. Finally, Renaissance Technologies LLC raised its position in Luminex by 18.0% in the first quarter. Renaissance Technologies LLC now owns 1,589,241 shares of the medical instruments supplier’s stock worth $29,194,000 after buying an additional 242,901 shares during the period. 74.41% of the stock is currently owned by hedge funds and other institutional investors.

Luminex Co. (LMNX) traded down 0.10% on Friday, hitting $19.19. 278,696 shares of the company were exchanged. Luminex Co. has a 52 week low of $17.64 and a 52 week high of $23.62. The company has a 50 day moving average price of $20.59 and a 200-day moving average price of $19.64. The stock has a market capitalization of $845.72 million, a P/E ratio of 59.41 and a beta of 0.29.

Luminex (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.11. Luminex had a net margin of 7.25% and a return on equity of 5.37%. The firm had revenue of $76.50 million for the quarter, compared to analysts’ expectations of $75.45 million. During the same quarter in the prior year, the business earned $0.33 EPS. The business’s quarterly revenue was up 19.2% on a year-over-year basis. On average, equities analysts expect that Luminex Co. will post $0.50 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 14th. Stockholders of record on Friday, June 23rd were paid a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 1.25%. The ex-dividend date was Wednesday, June 21st. Luminex’s dividend payout ratio (DPR) is presently 75.00%.

ILLEGAL ACTIVITY NOTICE: “Metropolitan Life Insurance Co. NY Has $519,000 Stake in Luminex Co. (NASDAQ:LMNX)” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/12/metropolitan-life-insurance-co-ny-has-519000-stake-in-luminex-co-nasdaqlmnx.html.

LMNX has been the topic of a number of recent analyst reports. TheStreet raised shares of Luminex from a “c+” rating to a “b-” rating in a research report on Friday, May 19th. Zacks Investment Research lowered shares of Luminex from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. ValuEngine lowered shares of Luminex from a “hold” rating to a “sell” rating in a research report on Saturday, July 8th. Jefferies Group LLC raised their price target on shares of Luminex from $20.00 to $21.00 and gave the company a “hold” rating in a research report on Tuesday, May 2nd. Finally, BidaskClub lowered shares of Luminex from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $21.67.

In other news, Director G Walter Loewenbaum II sold 25,000 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $20.23, for a total value of $505,750.00. Following the transaction, the director now owns 738,896 shares in the company, valued at approximately $14,947,866.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 75,000 shares of company stock worth $1,527,500 in the last quarter. Company insiders own 6.90% of the company’s stock.

About Luminex

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related companies with MarketBeat.com's FREE daily email newsletter.